📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:29
535 analysed today
FollowTelegram
535
Today
149,936
All-time analysed
42,982
Positive
6,669
Negative
91,578
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Q1 Net Profit Up 13.1% YoY to ₹0.65 Cr; Revenue Down 8.3% YoY to ₹6.93 Cr
Vasundhara Rasayans reported a 13.1% YoY increase in Net Profit after tax to ₹0.65 Cr (₹64.80 Lakhs) for the quarter ended June 30, 2026, up from ₹0.57 Cr (₹57.28 Lakhs) in the year-ago period. Net sales/income from operations fell 8.3% YoY to ₹6.93 Cr (₹693.23 Lakhs) from ₹7.56 Cr and declined 41.7% sequentially from ₹11.89 Cr in the preceding quarter. Total expenses dropped to ₹6.43 Cr from ₹7.47 Cr in Q1 FY26, aiding operating margins. Basic EPS for the quarter stood at ₹2.04 compared to ₹1.80 in Q1 FY26 and ₹7.80 in Q4 FY26.
Confidence: HIGH
What changedVasundhara Rasayans declared its unaudited financial results for the quarter ended June 30, 2026, showing YoY profit growth amidst declining revenue.
Why it mattersDemonstrates operating cost control and margin defense, though quarterly top-line volatility remains significant for this micro-cap business.
Revenue from operations (Q1): ₹693.23 LakhsNet Profit (Q1): ₹64.80 LakhsProfit Before Tax (Q1): ₹87.57 LakhsBasic EPS: ₹2.04Total Expenses (Q1): ₹642.53 Lakhs
📅 Short termMarket response is likely to be muted as the YoY bottom-line growth is counterbalanced by sequential top-line contraction.
📈 Long termLimited; quarterly performance reflects single-segment operations subject to ongoing cyclical variations.
⚠ Risk flags
- Quarterly top-line volatility with revenue declining 41.7% QoQ
- Single segment concentration risk (agri products)
Key Highlights
Revenue from operations fell 8.32% YoY to ₹693.23 Lakhs from ₹756.15 Lakhs
Net profit after tax increased 13.13% YoY to ₹64.80 Lakhs from ₹57.28 Lakhs
Total expenses dropped 14.00% YoY to ₹642.53 Lakhs compared to ₹747.10 Lakhs
Basic and diluted EPS stood at ₹2.04 compared to ₹1.80 in Q1 FY26 and ₹7.80 in Q4 FY26
👀 What to Watch
Monitor revenue recovery and capacity utilization in upcoming quarters following the sharp quarter-on-quarter drop from ₹11.89 Cr.
Vasundhara Rasayans Q1 Net Profit Up 14% YoY to ₹0.65 Cr Despite 8% Revenue Decline
Vasundhara Rasayans reported a mixed set of results for Q1 FY27 (ending June 2026), with Net Profit rising 14% YoY to ₹0.65 crore. However, Revenue from operations declined 8.3% YoY to ₹6.93 crore and saw a sharp sequential drop of 41.7% from the ₹11.89 crore reported in the March 2026 quarter. The profit growth amidst falling sales was primarily driven by a 39% reduction in 'Other Expenses' to ₹1.25 crore. EPS for the quarter stood at ₹2.04, up from ₹1.80 in the corresponding quarter last year.
Confidence: HIGH
What changedThe company has reported its first-quarter financial results for the fiscal year 2026-27, showing improved bottom-line efficiency despite a shrinking top line.
Why it mattersFor a micro-cap company with a ₹58 Cr market cap, maintaining profitability during revenue contractions is critical for debt management (currently ₹2 Cr) and investor confidence.
Net Sales (Q1): ₹6.93 CrNet Profit (Q1): ₹0.65 CrYoY Revenue Growth: -8.3%QoQ Revenue Growth: -41.7%EPS: ₹2.04
📅 Short termThe stock may see neutral to slightly cautious trading as the market weighs the YoY profit growth against the significant sequential revenue decline.
📈 Long termLimited structural significance; the company remains a small-scale player with volatile quarterly revenue patterns.
⚠ Risk flags
- Sharp sequential revenue decline (41.7%)
- Micro-cap liquidity risk
- High dependence on cost-cutting for profit growth
Key Highlights
Net Profit increased 13.1% YoY to ₹0.65 Cr from ₹0.57 Cr in June 2025
Revenue from operations fell 8.3% YoY to ₹6.93 Cr from ₹7.56 Cr
Other Expenses significantly reduced to ₹1.25 Cr from ₹2.04 Cr in the year-ago period
Sequential revenue declined by 41.7% compared to the March 2026 quarter (₹11.89 Cr)
Earnings Per Share (EPS) for the quarter improved to ₹2.04 from ₹1.80 YoY
👀 What to Watch
Investors should monitor the sustainability of cost-cutting measures and investigate if the 41.7% sequential revenue drop is due to seasonality in their agri-products segment or a loss of market share.
Vasundhara Rasayans FY26 Annual Report: Rs 2 Dividend Declared, PAT Grows 36% YoY
Vasundhara Rasayans has released its FY26 Annual Report, confirming a net profit of 5.79 cr on revenue of 35.72 cr. The board has recommended a final dividend of 2 per share (20% of face value), yielding approximately 1.14% at current prices. Export sales contributed 13.74 cr (38.5% of total revenue), while domestic sales stood at 21.99 cr. The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.04 and a healthy ROCE of 20%.
Confidence: HIGH
What changedFormal submission of the FY26 Annual Report and scheduling of the 39th AGM with a proposed 2 dividend.
Why it mattersConfirms the company's ability to grow profits (36% YoY) and maintain dividend payouts while operating with minimal debt in the pharmaceutical sector.
FY26 Revenue: 35.72 crFY26 Net Profit: 5.79 crFinal Dividend: 2 per shareExport Sales %: 38.5%Contingent Tax Liability: 60.20 lakhs
📅 Short termNeutral. The stock may see minor support from the dividend announcement, but the primary financial performance was already known through quarterly filings.
📈 Long termThe company shows consistent profitability and high capital efficiency (20% ROCE). Long-term value depends on scaling the revenue base beyond the current 36 cr level.
⚠ Risk flags
- Contingent liability of 60.20 lakhs regarding Income Tax disputes.
- Small market capitalization ( 56 cr) leading to potential liquidity risks.
- High concentration of management roles within the promoter family.
Key Highlights
Final dividend of 2 per equity share recommended for the financial year ended March 31, 2026.
Net profit for FY26 increased to 5.79 cr from 4.25 cr in the previous year, a 36% growth.
Export revenue recorded at 13.74 cr, accounting for 38.5% of the total 35.72 cr revenue.
Contingent liability of 60.20 lakhs reported for an Income Tax demand (AY 2015-16), representing ~10.4% of FY26 PAT.
CSR expenditure of 16.10 lakhs exceeded the statutory requirement of 14.10 lakhs.
👀 What to Watch
Monitor the AGM proceedings on August 25, 2026, and the subsequent record date for dividend payment. Investors should also track the resolution of the 60.20 lakh contingent tax liability.
Vasundhara Rasayans Proposes ₹2 Dividend and Significant ₹25 Cr Related Party Loan Limit
Vasundhara Rasayans has scheduled its 39th AGM for August 25, 2026, proposing a final dividend of ₹2 per share (20% of face value). The company is seeking shareholder approval for substantial related party transactions, including a ₹25 crore limit for loans or guarantees to P&J Cretechem Private Limited, which represents approximately 61% of the company's current net worth (₹41 cr). Additionally, sale/purchase limits of ₹15 crore each are proposed for the same entity, significant against a TTM revenue of ₹36 crore. Key management personnel, including the Managing Director and Whole-time Director, are up for five-year re-appointments.
Confidence: HIGH
What changedThe company has formalized its annual shareholder meeting agenda, including dividend declaration, management extensions, and new limits for related party financial dealings.
Why it mattersThe dividend provides a modest yield, but the high related party transaction limits (61% of net worth for loans) indicate significant financial inter-dependence with promoter-linked entities, which is a key governance factor for a micro-cap company.
Dividend per share: ₹2RPT Loan/Guarantee Limit: ₹25 crRPT Loan Limit vs Net Worth: ~61%RPT Sale/Purchase Limit (P&J): ₹15 crRPT Sale Limit vs TTM Revenue: ~42%MD Remuneration (Annual): ₹30,00,000
📅 Short termThe stock may see minor positive sentiment due to the dividend declaration; however, the procedural nature of the AGM notice typically has limited immediate price impact.
📈 Long termManagement stability is secured for 5 years. The structural reliance on related party transactions for a large portion of revenue and potential lending remains a key long-term monitoring point.
⚠ Risk flags
- High related party transaction limits relative to company size
- Significant potential for capital diversion via ₹25 cr loan/guarantee limit
- Promoter-heavy management structure
Key Highlights
Proposed final dividend of ₹2 per equity share for the financial year ended March 31, 2026.
Approval sought for related party transactions with P&J Cretechem Pvt Ltd involving loans/guarantees up to ₹25 crore.
Proposed sale and purchase limits of ₹15 crore each with P&J Cretechem, representing ~42% of TTM revenue.
Re-appointment of Rajesh Pokerna as Managing Director for 5 years with remuneration up to ₹30 lakh per annum.
Re-appointment of Seema Jain as Whole-time Director for 5 years with remuneration of ₹12 lakh per annum.
👀 What to Watch
Investors should monitor the AGM voting results, specifically the approval of high-value related party transactions and loan limits which impact capital allocation. Track the dividend payment timeline following the August 25 meeting.
₹2 Dividend Recommended and Re-appointment of MD & WTD for 5-Year Terms
Vasundhara Rasayans has recommended a dividend of ₹2 per equity share for FY26, which at the current price of ₹174.9 represents a yield of approximately 1.14%. The board also approved the re-appointment of Mr. Rajesh Pokerna as Managing Director and Smt. Seema Jain as Whole-time Director for five-year terms starting August 20, 2026. These leadership continuities follow a solid FY26 performance where the company reported a PAT of ₹5.79 Cr on revenue of ₹35.72 Cr. The 39th Annual General Meeting (AGM) and dividend eligibility cut-off is set for August 18, 2026.
Confidence: HIGH
What changedThe company has proposed a dividend payout for FY26 and secured the continuation of its top management for another five years.
Why it mattersFor a micro-cap company with a ₹56 Cr market cap, leadership stability and a consistent dividend payout (approx. 11% of FY26 EPS) are positive signals of operational maturity and governance.
Dividend per share: ₹2Dividend Yield: ~1.14%Re-appointment Tenure: 5 yearsCut-off Date: 18th August 2026FY26 Net Profit: ₹5.79 Cr
📅 Short termThe stock may see mild positive interest due to the dividend announcement and the removal of leadership uncertainty.
📈 Long termThe 5-year extension for the MD and WTD provides structural stability for the company's API manufacturing business.
⚠ Risk flags
- Related-party management (Seema Jain and Sunil Kumar Jain are relatives)
Key Highlights
Recommended a dividend of ₹2 per equity share for the financial year ended March 31, 2026
Re-appointed Rajesh Pokerna as Managing Director for a 5-year term from August 20, 2026, to August 19, 2031
Re-appointed Seema Jain as Whole-time Director for a 5-year term starting August 20, 2026
Fixed August 18, 2026, as the cut-off date for determining dividend eligibility and e-voting
Book closure period for the 39th AGM scheduled from August 19, 2026, to August 25, 2026
👀 What to Watch
Investors should note the August 18 cut-off date for dividend eligibility and monitor the 39th AGM for any strategic updates from the re-appointed leadership.
Rs 2 Dividend Recommended; MD and WTD Re-appointed for 5-Year Terms
Vasundhara Rasayans has recommended a dividend of Rs 2 per equity share for FY26, translating to a dividend yield of approximately 1.14% based on the current price of Rs 174.9. The Board also approved the re-appointment of Shri Rajesh Pokerna as Managing Director and Smt Seema Jain as Whole-time Director for five-year terms effective August 20, 2026. The company reported a steady FY26 with a PAT of Rs 5.79 Cr on a revenue of Rs 35.72 Cr. A cut-off date of August 18, 2026, has been set to determine eligibility for the dividend and e-voting for the 39th AGM.
Confidence: HIGH
What changedThe company has confirmed its dividend payout for FY26 and ensured leadership continuity by renewing the terms of its top management for another five years.
Why it mattersFor a micro-cap company with a market cap of Rs 56 Cr, leadership stability and a consistent dividend payout (yield of ~1.14%) are key indicators of corporate governance and financial health, especially given its high ROCE of 20%.
Dividend per share: Rs 2Dividend Yield: 1.14%Management Tenure Extension: 5 yearsDividend Cut-off Date: 18.08.2026TTM EPS: Rs 18.34
📅 Short termThe stock may see mild positive interest leading up to the August 18 cut-off date for the dividend.
📈 Long termManagement continuity is a positive sign for this small-scale pharma player; however, long-term re-rating depends on scaling its API revenue beyond the current Rs 36 Cr levels.
⚠ Risk flags
- Related-party relationship between Whole-time Directors (Seema Jain and Sunil Kumar Jain)
- Small scale of operations (Micro-cap risk)
Key Highlights
Recommended a dividend of Rs 2 per equity share for the financial year ended March 31, 2026.
Re-appointed Rajesh Pokerna as Managing Director for a 5-year term from August 20, 2026, to August 19, 2031.
Re-appointed Seema Jain as Whole-time Director for a 5-year term starting August 20, 2026.
Set the dividend and e-voting cut-off date as August 18, 2026.
Book closure period announced from August 19, 2026, to August 25, 2026, for the 39th AGM.
👀 What to Watch
Investors should note the cut-off date of August 18, 2026, for dividend eligibility and monitor the upcoming Annual Report for details on capacity utilization in their Antacid API manufacturing segment.
